Lilly partners with Ascidian to advance RNA editing therapies for kidney disease

Eli Lilly has entered into a major collaboration and licensing agreement with Ascidian Therapeutics to develop RNA exon-editing therapies for rare inherited kidney diseases. The deal, valued at up to $1.9 billion, gives Lilly exclusive, target-specific rights to Ascidian’s RNA exon-editing technology for certain undisclosed kidney disease targets.

The agreement reflects growing pharmaceutical interest in genetic medicines that may be able to address diseases at their molecular source. In this case, the focus is on monogenic kidney diseases, conditions caused by changes in a single gene, many of which currently have limited treatment options.

Ascidian’s technology is designed to edit RNA rather than permanently alter DNA. This is an important distinction. Traditional gene-editing approaches, including CRISPR-based methods, often focus on making changes at the DNA level. RNA exon editing aims to correct disease-causing genetic instructions at the RNA level, which could potentially offer some of the benefits of genetic correction while avoiding permanent changes to the genome.

Under the collaboration, Ascidian will lead early discovery and selected preclinical activities, while Lilly will be responsible for additional preclinical work, clinical development, manufacturing, and commercialization. Ascidian will also be eligible for milestone payments and royalties if therapies developed through the partnership reach the market.

For Lilly, the agreement adds to a broader push into genetic medicine. The company has recently pursued several partnerships and acquisitions in this space, including deals involving gene editing and AI-designed genetic medicine technologies.

For kidney disease, the collaboration is particularly notable because inherited kidney disorders can be difficult to treat with conventional approaches. Many of these diseases begin with a specific genetic defect but can progress to chronic kidney damage, reduced kidney function, and eventually the need for dialysis or transplantation. A therapy that targets the underlying genetic mechanism could, in theory, offer a more disease-modifying approach than treatments focused only on slowing progression.

Still, the deal remains at an early stage. The specific kidney disease targets have not been disclosed, and the therapies are not yet approved or available for clinical use. Much will depend on whether RNA exon editing can demonstrate safety, durability, and meaningful clinical benefit in future studies.

The Lilly–Ascidian partnership highlights a wider shift in drug development: genetic medicine is moving beyond rare eye, liver, and blood disorders into broader therapeutic areas, including kidney disease. For physicians, researchers, and patients, this may signal a new phase in which inherited kidney conditions become a more active focus for precision medicine innovation.

G-Med excels in HCP marketing by blending digital innovation with data-driven insights, creating an effective platform for reaching healthcare professionals, offering various advertising solutions. By using G-Med to engage HCPs, share data reports, and explore innovative channels, marketers can deliver targeted, impactful messages that foster strong connections. G-Med’s approach ensures that each campaign is tailored, scientifically rigorous, and effective, aligning perfectly with the best practices for successful HCP marketing.   

Contact us today to learn more: Contact@g-med.com